Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00408629 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 518
- Enrollment target
NCT00408629 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 518 participants.
The verdict
NCT00408629, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 518 participants
- Enrollment target
Study Summary
This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of the human anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab (ADA) in patients with moderately to severely active ulcerative colitis (UC).
Interventions
- BIOLOGICAL placebo
- BIOLOGICAL adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00408629
The ClinicalTrials.gov registry entry for NCT00408629 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00408629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00408629 about?
NCT00408629 is a clinical study titled "Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis". This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of the human anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab (ADA) in patients with moderately to severely active ulcerative colitis (UC).
What is the current status of trial NCT00408629?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 518 participants. The study started on 2006-11. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00408629?
The interventions under investigation include: placebo (BIOLOGICAL), adalimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00408629?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.